879085-55-9
2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide
CAS: 879085-55-9
Molecular Formula: C19H14Cl2N2O3S
879085-55-9 - Names and Identifiers
| Name | 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide |
| Synonyms | 101098 CS-1913 GDC-0449 Vismodegib GDC-0449,Vismodegib VisModegib (GDC-0449) 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide BenzaMide, 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(Methylsulfonyl)- |
| CAS | 879085-55-9 |
| EINECS | 806-752-3 |
| InChI | InChI=1/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24) |
879085-55-9 - Physico-chemical Properties
| Molecular Formula | C19H14Cl2N2O3S |
| Molar Mass | 421.3 |
| Density | 1.440 |
| Melting Point | 179-181°C |
| Boling Point | 561.6±50.0 °C(Predicted) |
| Flash Point | 293.4°C |
| Solubility | Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 10 mg/ml with warming) |
| Vapor Presure | 1.22E-12mmHg at 25°C |
| Appearance | White solid. |
| Color | Off-white or beige |
| pKa | 10.72±0.70(Predicted) |
| Storage Condition | -20° |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| Refractive Index | 1.64 |
| Use | Vismodegib (GDC-0449) is an effective, novel and specific hedgehog inhibitor with an IC50 of 3 nM. GDC-0449 also inhibited P-gp with an IC50 of 3.0 μM. |
879085-55-9 - Risk and Safety
| HS Code | 29333990 |
879085-55-9 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.374 ml | 11.868 ml | 23.735 ml |
| 5 mM | 0.475 ml | 2.374 ml | 4.747 ml |
| 10 mM | 0.237 ml | 1.187 ml | 2.374 ml |
| 5 mM | 0.047 ml | 0.237 ml | 0.475 ml |
Last Update：2024-01-02 23:10:35
879085-55-9 - Reference Information
| Overview | Vismodegib; it is one of the first anti-tumor drugs approved by the US Food and Drug Administration (FDA) for the treatment of advanced basal cell carcinoma (BCC) by Genentech Co., Ltd. on January 30, 2012. Since October 2012, Erivedge has been approved by the European Union, Switzerland, Australia, Israel, South Korea, Mexico and Ecuador. figure: vimodage |
| Use | for the treatment of locally progressive or metastatic basal cell carcinoma in adults who have relapsed after surgery or are not amenable to surgery or radiotherapy; basal cell carcinoma (BCC) is one of the most common forms of skin cancer. It originates from the surface of the skin and does not cause pain. For regular exposure to sunlight or ultraviolet radiation skin disease is the most likely. The R & D and marketing of vimodage has brought good news to BCC Patients. Its clinical role is important and the target market is huge, and it will grow into a "Giant Bomb" class (> $1 billion) drug in the future. pharmaceutical intermediates, intermediates in organic synthesis. |
| mechanism of action | vismopedage has a novel mechanism of action and is a selective Hedgehog signaling pathway inhibitor. Although Hedgehog signaling pathway is active in early life and plays an important role in regulating human growth and development, it is not active in adults. The vast majority of patients with basal cell carcinoma (>90%) have an overactive Hedgehog signaling pathway, which is considered to be the basic molecular driver of basal cell carcinoma. It acts as a competitive Cyclopamine antagonist and acts on the transmembrane G protein-coupled receptor protein (Smoothened) in the Hedgehog signaling pathway. It can block the expression of tumor-regulated genes related to Hedgehog signaling pathway by inhibiting SMO receptors to keep transcription factors GLT-1 and GLT-2 in a non-activated state. |
| synthetic route | figure: synthetic route |
| clinical trial procedure | wimodesgi is the first drug approved by the US FDA to date for the treatment of progressive basal cell carcinoma. The US FDA is mainly based on a Phase II International, multi-center, single-group, two-cohort, open-label clinical trial data of a study code shh4476 G. The trial included 96 patients with locally progressive (71) and metastatic (33) basal cell carcinoma, they were all treated with vimoidge 150 mg/d until disease progression or unacceptable toxicity, with the primary endpoint being the objective response rate as assessed by an independent panel of experts. Results: objective response rates were 43% and 33% for patients with locally progressive and metastatic basal cell carcinoma treated with vermoidgi, respectively, with a median response time of 7.6 months. |
| side effects | The most common side effects of vimodergine therapy include muscle cramps, hair loss, altered or lost sense of taste, weight loss, fatigue, Nausea, Diarrhea, decreased appetite, constipation, Vomit and Arthralgia. Vimodage is teratogenic and must be used as a contraceptive during treatment with the drug. |
| medication | The drug was administered on a QD oral regimen. |
| references | [1] Yang Mingrun. New anti-tumor drugs approved by FDA in 2012 [J]. Pharmaceutical Care and Research, 2013, 25 (4):304-306. [2] Tan Chuping, Shi Lili, Wang Shiwei, et al. Introduction and analysis of new drugs approved by FDA in 2012 [J]. Modern medicine and clinic, 2013, 28(3):415-420. [3] No. A new Roche drug, vimoidgi, for the treatment of metastatic basal cell carcinoma (BCC)[J]. Journal of Clinical rational use of drugs, 2015(17):158-158. [4] http://china.guidechem.com/trade/pdetail3020283.html |
| toxic substance data | information provided by: pubchem.ncbi.nlm.nih.gov (external link) |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Vismodegib (GDC-0449) Visit Supplier Webpage Request for quotationCAS: 879085-55-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Vismodegib (GDC-0449) Visit Supplier Webpage Request for quotationCAS: 879085-55-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History